Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of efficacy and safety of pazopanib and sunitinib in patients with metastatic renal cell carcinoma patients with poor-risk features

Trial Profile

Comparison of efficacy and safety of pazopanib and sunitinib in patients with metastatic renal cell carcinoma patients with poor-risk features

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top